Enterprise Value to EBITDA Multiple ratio Analysis of MedTech Acquisition Corp - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointLatest FY EV to EBITDA
Period Ending - Dec-22
Very Poor EV to EBITDA
58.36
Period Ending - Dec-21
Very Poor EV to EBITDA
73.19
Growth
-20.25 %
Trailing Twelve Months EV to EBITDA
Period Ending - Dec-22
Not Good EV to EBITDA
16.31
EV to EBITDA Analysis of MedTech Acquisition Corp
| Enterprise Value to EBITDA of MedTech Acquisition Corp with value of 58.36 implies that the company is overvalued. |
| EV to EBITDA Ratio of MTAC drastically fell by -20.25 % this year. |
Other EV to EBITDA Related Info of MTAC that may interest you.
MedTech Acquisition Corp Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| MTAC | 11.34 | 9.5559 | 18.67 % | Shell Companies |
Defination of Enterprise Value to EBITDA Multiple
Enterprise Value-to-EBITDA Ratio is used to compare a company's Enterprise Value to its EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization). It is useful to determine the value of a company, whether it is undervalued or overvalued. more ..
EV to EBITDA Related Ratios
| EBITDAMargin | EVToRevenue | PriceToEarningRatio |
Tsr Value Index
| Poor Value Stock | |
FY - Historical Enterprise Value to EBITDA Multiple of MedTech Acquisition Corp
| Period | Dec-22 | Dec-21 | Dec-20 |
|---|---|---|---|
| EV to EBITDA | 58.36 | 73.19 | -3356.05 |
| Change | -20.25 % | 102.18 % |
FY Chart of Enterprise Value to EBITDA Multiple of MedTech Acquisition Corp
Note : All Data Generated at the End of Trading Hours (EOD Data)